209 related articles for article (PubMed ID: 22919068)
21. FOXO3a: a novel player in thyroid carcinogenesis?
Karger S; Weidinger C; Krause K; Sheu SY; Aigner T; Gimm O; Schmid KW; Dralle H; Fuhrer D
Endocr Relat Cancer; 2009 Mar; 16(1):189-99. PubMed ID: 18845647
[TBL] [Abstract][Full Text] [Related]
22. CXCL12-induced upregulation of FOXM1 expression promotes human glioblastoma cell invasion.
Wang S; Zhang S; Li J; Xu X; Weng Y; Zheng M; Ouyang L; Li F
Biochem Biophys Res Commun; 2014 Apr; 447(1):1-6. PubMed ID: 24561124
[TBL] [Abstract][Full Text] [Related]
23. Deletion of Forkhead Box M1 transcription factor reduces malignancy in laryngeal squamous carcinoma cells.
Chen W; Yuan K; Tao ZZ; Xiao BK
Asian Pac J Cancer Prev; 2011; 12(7):1785-8. PubMed ID: 22126565
[TBL] [Abstract][Full Text] [Related]
24. Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression.
Zhang M; Liu Y; Gao Y; Li S
Eur J Pharmacol; 2015 Oct; 765():346-54. PubMed ID: 26342429
[TBL] [Abstract][Full Text] [Related]
25. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
Fan Q; Cai Q; Xu Y
Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
[TBL] [Abstract][Full Text] [Related]
26. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
27. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.
Lok GT; Chan DW; Liu VW; Hui WW; Leung TH; Yao KM; Ngan HY
PLoS One; 2011; 6(8):e23790. PubMed ID: 21858223
[TBL] [Abstract][Full Text] [Related]
28. SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.
Wang P; Shang J; Zhao J; Wang K; Guo L; Gu J; Wang W
Mol Med Rep; 2020 Mar; 21(3):1201-1207. PubMed ID: 31922212
[TBL] [Abstract][Full Text] [Related]
29. FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway.
Yu G; Zhou A; Xue J; Huang C; Zhang X; Kang SH; Chiu WT; Tan C; Xie K; Wang J; Huang S
Oncotarget; 2015 May; 6(13):11281-94. PubMed ID: 25869208
[TBL] [Abstract][Full Text] [Related]
30. GAB1 is upregulated to promote anaplastic thyroid cancer cell migration through AKT-MDR1.
Song P; Xu H; He Y; Sun J; Xu Z; Huang P; Ge M; Zhang X; Ke Y; Cheng H
Biochem Biophys Res Commun; 2022 Jun; 607():36-43. PubMed ID: 35366541
[TBL] [Abstract][Full Text] [Related]
31. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
Nakamura S; Hirano I; Okinaka K; Takemura T; Yokota D; Ono T; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
Carcinogenesis; 2010 Nov; 31(11):2012-21. PubMed ID: 20823107
[TBL] [Abstract][Full Text] [Related]
32. LXRα-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells.
Hu C; Liu D; Zhang Y; Lou G; Huang G; Chen B; Shen X; Gao M; Gong W; Zhou P; Dai S; Zeng Y; He F
Oncogene; 2014 May; 33(22):2888-97. PubMed ID: 23812424
[TBL] [Abstract][Full Text] [Related]
33. Aberrant l1 cell adhesion molecule affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma.
Kim KS; Min JK; Liang ZL; Lee K; Lee JU; Bae KH; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Choi MJ; Jo YS; Kim JM; Shong M
Clin Cancer Res; 2012 Jun; 18(11):3071-8. PubMed ID: 22472175
[TBL] [Abstract][Full Text] [Related]
34. Investigation of FOXM1 as a Potential New Target for Melanoma.
Miyashita A; Fukushima S; Nakahara S; Yamashita J; Tokuzumi A; Aoi J; Ichihara A; Kanemaru H; Jinnin M; Ihn H
PLoS One; 2015; 10(12):e0144241. PubMed ID: 26640950
[TBL] [Abstract][Full Text] [Related]
35. [Effects of AG1478 on the expression of FOXM1 gene via FOXO3a in non-small cell lung cancer cells].
Gong XD; Yuan HH; Wang JY; Guo YH; Shi J; Jiang B
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):572-8. PubMed ID: 24314213
[TBL] [Abstract][Full Text] [Related]
36. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
[TBL] [Abstract][Full Text] [Related]
37. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance.
Gomes AR; Zhao F; Lam EW
Chin J Cancer; 2013 Jul; 32(7):365-70. PubMed ID: 23706767
[TBL] [Abstract][Full Text] [Related]
38. Broussoflavonol B from
Jeong JH; Ryu JH
Molecules; 2020 May; 25(10):. PubMed ID: 32429421
[TBL] [Abstract][Full Text] [Related]
39. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
[TBL] [Abstract][Full Text] [Related]
40. Silencing of FOXM1 transcription factor expression by adenovirus-mediated RNA interference inhibits human hepatocellular carcinoma growth.
Chen T; Xiong J; Yang C; Shan L; Tan G; Yu L; Tan Y
Cancer Gene Ther; 2014 Mar; 21(3):133-8. PubMed ID: 24577129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
